Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL237 in APDS/PASLI
CTR20241126Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CVL237 in Activated PI3Kδ syndrome (APDS), sponsored by Convalife Pharmaceutical. Started May 2024; status: active.
02
Drugs
CVL237
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on CTR20241126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241126.